CAY10595, with the CAS number 916047-16-0, is a chemical compound that functions primarily as a selective inhibitor of the enzyme phosphodiesterase 4 (PDE4). This inhibition plays a significant role in modulating inflammatory responses and has potential therapeutic applications in various conditions, including respiratory diseases and neurodegenerative disorders. CAY10595 is characterized by its ability to enhance intracellular levels of cyclic AMP (cAMP), which is crucial for numerous cellular signaling pathways. The compound is typically studied in the context of its pharmacological effects, including anti-inflammatory properties and potential neuroprotective effects. Its chemical structure includes specific functional groups that contribute to its biological activity and selectivity for PDE4 over other phosphodiesterases. As with many research chemicals, safety and handling precautions are essential, and its use is generally confined to laboratory settings for research purposes. Further studies are often required to fully elucidate its mechanisms of action and potential clinical applications.

The biological effects of prostaglandin D
2
(PGD
2
) are transduced by at least two 7-
transmembrane G protein-
coupled receptors, designated DP
1
and CRTH2/DP
2
. In humans, CRTH2/DP
2
is expressed on Th2 cells, eosinophils, and basophils where it mediates the chemotactic activity of PGD
2
.
1
CAY10595, as a racemic mixture, is a potent CRTH2/DP
2
receptor antagonist that binds to the human receptor with a K
i
value of 10 nM.
2
The R enantiomer of CAY10595 is significantly more potent exhibiting K
i
values of 5.3 and 5 nM at the human and murine CRTH2/DP
2
receptor, respectively. The R enantiomer of CAY10595 inhibits eosinophil chemotaxis induced by 13,14-
dihydro-
15-
keto-
PGD
2
with an IC
50
value of 7.3 nM.
2

CAY10595

916047-16-0: CAY10595, with the CAS number 916047-16-0, is a chemical compound that functions primarily as a selective inhibitor of the enzyme phosphodiesterase 4 (PDE4). This inhibition plays a significant role in modulating inflammatory responses and has potential therapeutic applications in various conditions, including respiratory diseases and neurodegenerative disorders. CAY10595 is characterized by its ability to enhance intracellular levels of cyclic AMP (cAMP), which is crucial for numerous cellular signaling pathways. The compound is typically studied in the context of its pharmacological effects, including anti-inflammatory properties and potential neuroprotective effects. Its chemical structure includes specific functional groups that contribute to its biological activity and selectivity for PDE4 over other phosphodiesterases. As with many research chemicals, safety and handling precautions are essential, and its use is generally confined to laboratory settings for research purposes. Further studies are often required to fully elucidate its mechanisms of action and potential clinical applications.

CAY10595 is an antagonist of the CRTh2 (DP2) receptor with a Ki of 10 nM.

CAS 916047-16-0

CAY10595

CAY10595

Ref: 54-BUP07101

CAY10595

Ref: TM-T10691